Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Xifaxan 550 Mg Tabs 60 Unit Dose By Valeant Pharma

Image 0 of Xifaxan 550 Mg Tabs 60 Unit Dose By Valeant PharmaImage 1 of Xifaxan 550 Mg Tabs 60 Unit Dose By Valeant Pharma

Xifaxan 550 Mg Tabs 60 Unit Dose By Valeant Pharma

Call for Price

Xifaxan 550 Mg Tabs 60 Unit Dose By Valeant Pharma This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXB10009439/RXD4301313/RXa903039/RXA312046
Size : 60
Selling UoM : EA
NDC: 65649-0303-03
UPC Barcode : 365649303036
Supplier: 0050001428 VALEANT PHARMACEUTICALS INT'L
Supplier Material : 030303
Generic Code : 066295 RIFAXIMIN ORAL TABLET 550 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded

Have a question?

  Call for Price

Product Description.:

rfx
tablet , pink , oval oblong
BiconvexDebossed

Introducing Xifaxan550
Efficacy and tolerability for control of hepatic encephalopathy (HE)

* Xifaxan 550 mg (rifaximin) reduces the risk of overt HE recurrence and reduces HE-related hospitalizations.1
* Xifaxan 550 mg is nonsystemic to provide safety and tolerability when used as directed.1
* Xifaxan 550 mg offers twice-daily dosing.1
* Xifaxan 550 mg is believed to regulate gut flora balance for control of HE.

XIFAXAN 550 mg (rifaximin) approved for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients �� years of age. XIFAXAN 550 mg is a nonsystemic treatment option providing efficacy and tolerability for control of HE recurrence.

HE is a disease marked by an intractable cycle of relapse and remission, followed almost inevitably by relapse. Episodes of acute encephalopathy can be reversed however, people with chronic liver disease are consistently susceptible to future relapse.1 It is estimated that 50% to 70% of cirrhotic patients will go on to develop overt HE.2

XIFAXAN 550 mg is proven to reduce the risk of overt HE recurrence and reduce HE-related hospitalizations over a 6-month period.3 Treatment with XIFAXAN 550 mg is believed to affect gut flora balance for control of HE.3,4

IMPORTANT SAFETY INFORMATION

XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients �� years of age. In the trials of XIFAXAN for HE, 91% of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores >25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon which may lead to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

The most common adverse reactions occurring in >8% of patients in the clinical study were edema peripheral (15%), nausea (14%), dizziness (13%), fatigue (12%), ascites (11%), muscle spasms (9%), pruritus (9%), and abdominal pain (9%).

Click Here for Prescribing Information